SNCA and Parkinson disease: Other studies have reported similar results of FTIs towards reducing protein aggregates; treating cell culture models of PD with FTI-277 reduced α-synuclein [28] and lonafarnib, an FDA-approved FTI for the treatment of progeria [29], increased lysosomal activity and reduced tau inclusions in a mouse model of tauopathy [9].